Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.53 |
| ▸ | MMP9 | P14780 | 8/20 | 0.53 |
| ▸ | MMP8 | P22894 | 8/20 | 0.53 |
| ▸ | MMP13 | P45452 | 8/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152066 | 0.91 | MMP2 (0.46) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL13741534 | 0.87 | MAPT (0.50) | MMP2MMP9MMP8MMP13HDAC6 | |
| SCHEMBL4148808 | 0.87 | HDAC6 (0.52) | SIRT2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL4146845 | 0.87 | HDAC6 (0.52) | HDAC6PTGDR2 | |
| SCHEMBL4147631 | 0.86 | NPBWR1 (0.50) | SIRT2SIRT1SIRT3PTGDR2 | |
| SCHEMBL4160495 | 0.85 | MMP2 (0.71) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL4149005 | 0.85 | MMP2 (0.69) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL13751458 | 0.80 | PRMT5 (0.50) | HDAC6PTGDR2 | |
| SCHEMBL4148796 | 0.79 | HDAC6 (0.45) | SIRT2HDAC6SIRT1SIRT3KDR | |
| SCHEMBL4160681 | 0.79 | EGLN1 (0.41) | SIRT2HDAC6SIRT1SIRT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | claimed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | claimed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | claimed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | claimed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8436022-B2 | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | TRPV1, TRPV3, TRPV5 | MMP2 1846/4885MMP9 3310/4885MMP8 673/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | MMP2 2548/4885MMP9 4054/4885MMP8 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.